MedZora Article

Early Biologic Therapy in Inflammatory Bowel Disease: Why "Waiting" May Not Be the Safest Choice

Inflammatory bowel disease (IBD) - which includes Crohn's disease and ulcerative colitis - can be unpredictable. Some people experience mild symptoms that come and go, while others develop ongoing inflammation that damages the gut lining. For many years the standard practice was to start with simple medicines such as aminosalicylates or steroids, and only move to stronger biologic drugs if those first‑line options failed. This "step‑up" method still guides treatment in many clinics.

In recent years a different strategy, often called "top‑down", has gained attention. The idea is to introduce biologic therapy - a class of medicines that target specific parts of the immune system - early in the disease course, rather than waiting for multiple treatment failures. Two large studies, REACT and SONIC, have contributed important data to this discussion.

What the "Top‑Down" Approach Means

Biologic agents used in IBD include anti‑TNF (tumor‑necrosis‑factor) drugs and integrin‑targeting agents. They work by dampening the inflammatory signals that drive gut damage. In a top‑down plan, a gastroenterology team may suggest one of these biologics soon after diagnosis, especially if the disease shows signs of aggressive behavior (for example, deep ulcers, frequent flares, or early need for steroids).

The traditional step‑up approach begins with milder medications, adds immunomodulators such as azathioprine if needed, and finally turns to biologics when the earlier steps do not control symptoms. The rationale for waiting has been to limit exposure to powerful drugs that can affect the immune system.

Why Early Intervention May Be Helpful

The REACT (Randomized Evaluation of Early and Intravenous Treatment) trial examined patients with moderate‑to‑severe Crohn's disease. Participants were randomly assigned to receive early anti‑TNF therapy plus standard care, or standard care alone with biologics added later if needed. After 48 weeks, the early‑treatment group showed higher rates of mucosal healing - meaning the lining of the intestine appeared normal on endoscopy - compared with the delayed‑treatment group. Mucosal healing has been linked in several studies to lower risk of future flares and surgery, although not every patient who heals will stay flare‑free.

The SONIC (Study of Biologic and Immunomodulator Naïve Patients in Crohn's Disease) trial focused on patients who had not previously taken immunomodulators or biologics. In this study, early combination therapy with an anti‑TNF agent and a thiopurine (a type of immunomodulator) resulted in higher remission rates and more frequent mucosal healing than either drug alone. The trial also reported fewer hospital admissions for IBD complications in the combination group during the first year of treatment.

Together, these studies suggest that starting biologic therapy early - either alone or together with an immunomodulator - may improve short‑term outcomes such as symptom control and intestinal healing. They also hint at a possible reduction in serious events like hospitalisation or need for surgery. However, it is important to recognise that the benefits observed in trials may not be identical for every individual. Response to biologics varies, and some patients may achieve good control with less intensive therapies.

Potential Risks of Waiting

Delaying biologic treatment can have consequences, particularly for people whose disease shows rapid progression. Persistent inflammation can lead to strictures (narrowing of the bowel), fistulas (abnormal connections between organs), and malnutrition. In severe cases, patients may need emergency hospital stays or surgeries that could have been avoided with earlier control of inflammation.

On the other hand, biologic agents are not without risks. Because they modulate the immune system, they may increase susceptibility to infections, including respiratory or gastrointestinal infections. Rare but serious complications such as reactivation of latent tuberculosis or certain viral infections have been reported. Screening for infections before starting therapy and regular monitoring while on treatment are standard safety measures.

Balancing Benefits and Risks

Choosing between a top‑down and step‑up approach is a shared decision that should involve the patient, their gastroenterology team, and sometimes other specialists such as surgeons or nutritionists. Factors that often influence the decision include:
- Disease severity at diagnosis - deep ulcers, extensive inflammation, or signs that the disease may become complicated.
- Frequency of flares - multiple relapses in a short period may suggest a more aggressive disease.
- Personal preferences - some patients prefer to avoid the possibility of surgery even if that means using stronger medicines early.
- Lifestyle considerations - work, travel, and family responsibilities can affect how a patient tolerates frequent clinic visits or infusion appointments.
- Safety profile - any history of infections, liver disease, or other health issues that could raise the risk of biologic therapy.

When the decision leans toward early biologic use, clinicians generally follow a structured plan: confirm the diagnosis with endoscopy and imaging, screen for infections (including hepatitis B and C, HIV, and tuberculosis), and discuss the potential benefits and side effects openly. Patients are encouraged to report new symptoms promptly, such as fever, cough, or unusual skin changes, as these may signal an infection that needs evaluation.

What Patients Can Do Now

If you have been diagnosed with Crohn's disease or ulcerative colitis, consider the following steps:

1. Ask for a clear explanation of your disease activity. Endoscopic findings and imaging can help gauge how much of the gut is inflamed.
2. Discuss the possibility of early biologic therapy with your gastroenterologist. Request information about the specific class of biologic that might be appropriate for you.
3. Inquire about the screening tests that will be performed before starting any biologic. Knowing what to expect can reduce anxiety.
4. Keep a symptom diary. Recording stool frequency, abdominal pain, weight changes, and energy levels can help your doctor assess whether the current treatment is working.
5. Review vaccination status. Certain vaccines (for example, flu and pneumococcal) are recommended before biologic therapy, while live vaccines are generally avoided during treatment.
6. Stay aware of any signs of infection. Prompt medical attention can prevent a minor issue from becoming serious.
7. Consider lifestyle factors that support gut health, such as a balanced diet, regular exercise, stress management, and smoking cessation, if applicable.

The decision to start a biologic early is not a one‑size‑fits‑all prescription. It is a carefully weighed option that aims to control inflammation before it causes irreversible damage. Ongoing research continues to refine which patients are most likely to benefit from this strategy. As evidence evolves, your healthcare team will adjust recommendations to match your individual needs.

Closing Thoughts

Early biologic therapy offers a promising pathway for many living with IBD, especially those with signs of aggressive disease. Clinical trials like REACT and SONIC have shown that starting powerful treatments sooner can lead to higher rates of intestinal healing and may lower the chance of hospitalisation in the short term. Yet, these benefits come with potential risks that require vigilant screening and monitoring. Open dialogue with your gastroenterology specialist remains the cornerstone of a treatment plan that balances efficacy with safety.

This article provides general information and does not replace personalized medical advice. Please discuss your specific situation with your own clinician before making any changes to your treatment plan.